Clinical Trial Update: Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating the safety and immune response of an HIV-1 DNA vaccine in HIV-uninfected adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC-HIVDNA009-00-VP (HIV DNA vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED